Press Release
Category Added in a WPeMatico Campaign
-
Business Wire19 April 2026
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms
BEIJING–(BUSINESS WIRE)–Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing…
Read More » -
Business Wire19 April 2026
Amplitude Research Reveals a Generational AI Trust Gap is Costing Australian Businesses
New research suggests senior leaders’ distrust of AI is driving inefficient implementation and widening Australia’s AI skills gap. SYDNEY–(BUSINESS WIRE)–New…
Read More » -
Business Wire19 April 2026
Best’s Market Segment Report: Australia’s Non-Life Insurance Segment Navigating Growth in a Volatile Landscape
SINGAPORE–(BUSINESS WIRE)–#insurance–Australia’s non-life insurance industry has been resilient against an increasingly complex and interconnected risk landscape, with total insurance revenue…
Read More » -
Cision PR Newswire19 April 2026
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk’s proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions…
Read More » -
Business Wire19 April 2026
Synthetic Design Lab Unveils First Advanced Logic-Gated ADC at AACR 2026, Achieving ≥10X Improvement in Targeted Cancer Cell Killing
SYNTHBODY™ introduces a new class of “smart drugs”: protein therapeutics with built-in, multi-layered logic gates that actively change how they…
Read More » -
Business Wire19 April 2026
EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors
First-in-human study of EPI-326 will evaluate the company’s lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential…
Read More » -
Business Wire19 April 2026
EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors
First-in-human study of EPI-326 will evaluate the company’s lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential…
Read More » -
Cision PR Newswire19 April 2026
Sidus Space Announces Pricing of $58.5 Million Registered Direct Offering of Class A Common Stock
CAPE CANAVERAL, Fla., April 19, 2026 /PRNewswire/ — Sidus Space, Inc. (Nasdaq: SIDU) (“Sidus” or the “Company”), an innovative space…
Read More » -
Balla19 April 2026
Video Lecture Summarizer: How to Learn Faster Without Rewatching Everything
Online learning has made education more flexible, but it has also created a new problem. There is now too much…
Read More » -
Cision PR Newswire19 April 2026
SIRUI Wins “Best of Show”, Unveils New Cine Lenses at NAB Show 2026
LAS VEGAS, April 19, 2026 /PRNewswire/ — SIRUI today received a “Best of Show” award for its Vision Prime T1.4…
Read More »


